祛湿活血退黄散治疗原发性胆汁性肝硬化患者60例临床观察

Clinical observation on treating 60 cases of PBC with Qushi Huoxue Tuihuang San

目的：观察祛湿活血退黄散联合熊去氧胆酸胶囊治疗原发性胆汁性肝硬化的临床疗效。方法：将60例PBC患者随机分为治疗组和对照组各30例。对照组给予熊去氧胆酸胶囊13～15mg?kg-1?d-1，3次/d；治疗组在对照组治疗基础上加用祛湿活血退黄散，1剂/d，两组疗程均为24周。观察两组患者治疗前后血中TBIL、ALP、GGT、Th17、IL-17A指标变化情况。结果：两组患者治疗后TBIL、ALP、GGT、Th17、IL-17A指标水平与治疗前比较均明显降低（P<0.05），且治疗组患者TBIL、ALP、GGT、Th17、IL-17A指标水平与对照组比较降低更为显著（P<0.05）。结论：祛湿活血退黄散联合熊去氧胆酸胶囊治疗PBC在降低TBIL、ALP、GGT、Thl7和IL-17A指标方面优于单用熊去氧胆酸胶囊。

Objective: To observe clinical efficacy of Qushi Huoxue Tuihuang San plus ursodeoxycholic acid capsules on primarybiliary cirrhosis. Methods: 60 patients were randomly divided into the treatment group and control group, 30 cases in each. The controlgroup was given ursodeoxycholic acid capsules (13~15mg?kg-1?d-1, 3 times daily). The treatment group was treated with Qushi HuoxueTuihuang San (3times daily) more. Two groups were treated for 24 weeks. The blood TBIL, ALP, GGT, Th17, IL-17A index were observed.Results: The blood TBIL, ALP, GGT, Th17, IL-17A indexes were significantly decreased (P<0.05); those were more significantly decreasedin the treatment group (P<0.05). Conclusion: Treating PBC with Qushi Huoxue Tuihuang San plus ursodeoxycholic acid capsules shows abetter effect, and reduce the TBIL, ALP, GGT, Th17 and IL-17A indexes.